We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $999B
1-Year Est. Return 46.22%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+29.22%
1 Year Est. Return
+46.22%
3 Year Est. Return
+150.45%
5 Year Est. Return
+185.95%
10 Year Est. Return
+871.56%
AUM
$999B
AUM Growth
+$134B
Cap. Flow
-$3.54B
Cap. Flow %
-0.35%
Top 10 Hldgs %
32.24%
Holding
3,356
New
224
Increased
2,237
Reduced
645
Closed
116

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$12.1B
2
AAPL icon
Apple
AAPL
+$11.6B
3
AMZN icon
Amazon
AMZN
+$3.54B
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$3.07B
5
KEYS icon
Keysight
KEYS
+$1.82B

Sector Composition

Rank Sector Weight
1 Technology 37.73%
2 Healthcare 11.3%
3 Financials 10.32%
4 Communication Services 9.66%
5 Industrials 9.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LPCN icon
3201
Lipocine
LPCN
$18.5M
$32K ﹤0.01%
+12,266
New +$29.5K
LPSN
3202
DELISTED
LivePerson
LPSN
$32K ﹤0.01%
16,600
STIM icon
3203
Neuronetics
STIM
$232M
$32K ﹤0.01%
24,246
-12,615
-34% -$18.4K
NGEN
3204
NervGen Pharma
NGEN
$229M
$32K ﹤0.01%
15,504
CNTB
3205
Connect Biopharma Holdings
CNTB
$127M
$30K ﹤0.01%
+12,469
New +$30.2K
CYN icon
3206
Cyngn
CYN
$12M
$30K ﹤0.01%
20,900
DARE icon
3207
Dare Bioscience
DARE
$14.1M
$29K ﹤0.01%
13,318
+3,096
+30% +$6.92K
NPWR icon
3208
NET Power
NPWR
$164M
$29K ﹤0.01%
17,028
JELD icon
3209
JELD-WEN Holding
JELD
$182M
$28K ﹤0.01%
18,400
-58,418
-76% -$90K
SST icon
3210
System1
SST
$38.4M
$28K ﹤0.01%
+11,731
New +$36.8K
WVVI icon
3211
Willamette Valley Vineyards
WVVI
$10.4M
$28K ﹤0.01%
10,850
HSDT icon
3212
Solana Company
HSDT
$133M
$26K ﹤0.01%
15,700
OPAL icon
3213
OPAL Fuels
OPAL
$56M
$24K ﹤0.01%
10,821
SKYA
3214
SkyAI Inc
SKYA
$55.8M
$24K ﹤0.01%
20,800
TNYA icon
3215
Tenaya Therapeutics
TNYA
$148M
$24K ﹤0.01%
31,453
BEEM icon
3216
Beam Global
BEEM
$30.9M
$23K ﹤0.01%
16,988
FDN icon
3217
First Trust Dow Jones Internet Index Fund ETF
FDN
$5.3B
$23K ﹤0.01%
+85
New +$22.4K
LVWR icon
3218
LiveWire
LVWR
$234M
$21K ﹤0.01%
18,339
MERC icon
3219
Mercer International
MERC
$25.7M
$16K ﹤0.01%
23,005
+5,346
+30% +$5.32K
NFE icon
3220
New Fortress Energy
NFE
$77.9M
$14K ﹤0.01%
36,811
-117,736
-76% -$70K
FHLC icon
3221
Fidelity MSCI Health Care Index ETF
FHLC
$3.41B
$6K ﹤0.01%
+74
New +$5.32K
OPENW
3222
Opendoor Technologies Inc Series K Warrants
OPENW
$4.81M
$6K ﹤0.01%
+10,488
New +$6.3K
HSBC icon
3223
HSBC
HSBC
$360B
$3K ﹤0.01%
+24
New +$2.19K
OPENL
3224
Opendoor Technologies Inc Series A Warrants
OPENL
$3.3M
$3K ﹤0.01%
+10,489
New +$3.22K
OPENZ
3225
Opendoor Technologies Inc Series Z Warrants
OPENZ
$3.16M
$3K ﹤0.01%
+10,489
New +$3K

Similar funds

T. Rowe Price Associates's Q2 2026 Portfolio in Review

As of Q2 2026, T. Rowe Price Associates held 3,356 positions worth $999B, up 16% from $865B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

T. Rowe Price Associates's Q2 2026 filing shows 224 new, 2,237 increased, 645 reduced and 116 closed positions. Its largest new stake was SpaceX: 10,709,016 shares worth $1.83B. The largest sale was Microsoft, an estimated $12.1B.

By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 34% a quarter earlier, followed by Healthcare and Financials.

  • T. Rowe Price Associates's largest Q2 2026 buy was SpaceX: 10,709,016 shares worth $1.83B.
  • T. Rowe Price Associates added most to Alphabet (Google) Class A in Q2 2026, an estimated $7.49B increase.
  • T. Rowe Price Associates's biggest Q2 2026 reduction was Microsoft, cutting an estimated $12.1B.
  • T. Rowe Price Associates fully exited Sibanye-Stillwater in Q2 2026, selling an estimated $40.4M.
  • T. Rowe Price Associates's ten largest holdings make up 32% of its $999B portfolio in Q2 2026.
  • T. Rowe Price Associates opened 224 new positions and closed 116 in Q2 2026.
  • T. Rowe Price Associates's portfolio value rose 16% quarter-over-quarter to $999B.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.